Optimal dose of pretreated-dexmedetomidine in fentanyl-induced cough suppression: a prospective randomized controlled trial

Wei Zhou
School of medicine, yangzhou University  https://orcid.org/0000-0003-0221-2480

Dongsheng Zhang
The Affiliated Hospital of Yangzhou University

Shunping Tian
School of Medicine, yangzhou University

Yang Yang
The Affiliated Hospital of Yangzhou University

Zhi Xing
The Affiliated Hospital of Yangzhou University

Rongrong Ma
The Affiliated Hospital of Yangzhou University

Tianqi Zhou
The Affiliated Hospital of Yangzhou University

Tianxiu Bao
The Affiliated Hospital of Yangzhou University

Jianhong Sun
The Affiliated Hospital of Yangzhou University

Zhuan Zhang (✉ zhangzhuancg@163.com)
https://orcid.org/0000-0002-7295-9013

Research article

Keywords: Dexmedetomidine; Fentanyl; Cough

Posted Date: May 20th, 2019

DOI: https://doi.org/10.21203/rs.2.344/v4

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Version of Record: A version of this preprint was published on June 1st, 2019. See the published version at https://doi.org/10.1186/s12871-019-0765-z.
Abstract

Background: To investigate the optimal dose of pretreated-dexmedetomidine in fentanyl-induced cough (FIC) suppression. Methods: Patients of 180 undergoing elective surgery with general anesthesia, aged 18-65 years, BMI 18.5-30 kg/m², ASA I or II, were equally randomized into four groups (n = 45) to receive intravenous pretreatment of dexmedetomidine with 0 (group 1), 0.3 (group 2), 0.6 (group 3) and 0.9 (group 4) mcg/kg over 10 mins, respectively. After the pretreatment, all patients were given a 5-s intravenous injection of fentanyl 4 mcg/kg. The symptoms of irritating cough including the severity and onset time were recorded for 1 min after fentanyl injection. General anesthesia induction was completed with midazolam, propofol and cisatracurium, then endotracheal tube or laryngeal mask was inserted and connected to an anesthesia machine. MAP, HR and SpO₂ at the beginning of pretreatment (T0), 3 min (T1), 6 min (T2), 9 min (T3) and 12 min (T4) after the beginning of pretreatment were recorded. Side effects of dexmedetomidine, such as bradycardia, hypertension, hypotension, and respiratory depression were also recorded during the course. Results: Totally 168 patients completed the study. The incidences of cough were 52.4%, 42.9%, 11.9%, and 14.3% in groups 1, 2, 3, and 4, respectively, with no significant differences between groups 1 and 2 (P > 0.05) and between groups 3 and 4 (P > 0.05). The incidence and severity of cough in groups 3 and 4 were significantly lower than those in groups 1 and 2 (P < 0.05). Compared to T0, HR at T2 (P < 0.05), T3 (P < 0.01), and T4 (P < 0.01) decreased significantly and MAP at T4 decreased significantly (P < 0.05) in group 4. Bradycardia occurred in 1 case and respiratory depression occurred in 1 case in group 4. Compared to group 1, the onset time of cough in the other 3 groups were delayed significantly (P < 0.05). Conclusion: Pretreated dexmedetomidine 0.6 mcg/kg blous intravenous infusion over 10 mins could reduce FIC effectively without side effects.

Background

Fentanyl is used widely for general anesthesia induction due to its rapid onset, intensive analgesia and cardiovascular stability; however, an irritating cough may be caused after its intravenous (IV) administration [1]. The incidence of fentanyl-induced cough (FIC) can reach 80% [2]. The FIC may be transitory and limited; however, it can be explosive and detrimental especially in patients with increased intracranial, intraocular, intrathoracic, or intra-abdominal pressure [3-5]. FIC could even cause severe upper airway obstruction and aspiration pneumonia that require immediate intervention [6, 7]. A report that explosive FIC produced multiple conjunctival and periorbital petechiae has been published [8]. FIC needs immediate and effective intervention especially in patients with cerebral aneurysm, brain trauma, hernia, open eye injury, dissecting aortic aneurysm, pneumothorax or hypersensitive airway disease. Precaution of FIC in these situations is of great importance.

The mechanism of FIC has not been elucidated definitely, although various studies have been conducted to suppress or alleviate this side effect [4, 9]. A previous study has shown that intravenous clonidine could suppress FIC effectively through its α₂-adrenoceptor agonist effect [10]. Dexmedetomidine, a highly selective α₂-adrenoceptor agonist, is widely used for its particular virtues, such as favorable sedative and analgesic effects. It can also reduce central sympathetic outflow and stress response [11]. A previous
study has shown the suppressing effect of dexmedetomidine combined with midazolam on FIC [12]. While another study reported that better cough suppression was found at 1 mcg/kg vs. 0.5 mcg/kg dexmedetomidine bolus without an increase in side effects [13]. However, we should be concerned about its antisympathetic responses with higher doses of dexmedetomidine. Therefore, we designed a study to investigate the optimal priming dose of dexmedetomidine in FIC suppression during general anesthesia induction.

Full Text

Background

Results

Conclusion

Abbreviations

Declarations

References

Parameters

Group 1

Group 2

Group 3

Group 4

Age (years)

46.8±14.3

49.9±11.8

47.3±13.4
|                | Group 1 | Group 2 | Group 3 | Group 4 |
|----------------|---------|---------|---------|---------|
| Gender (males/females) | 19/23   | 20/22   | 18/24   | 21/21   |
| Weight (kg)      | 68.6±11.8 | 69.8±10.6 | 65.7±12.6 | 63.4±9.8 |
| BMI (kg/cm²)     | 24.5±2.8  | 25.1±3.2  | 24.2±3.6  | 23.0±2.3  |
| ASA (I/II)       | 24/18    | 26/16    | 26/16    | 25/17    |

Table 1. Demographic characteristics of patients in the four groups.

Values are mean ± standard deviation.
| Group     | Onset time (s, x ± s) | Incidence (n, %) | Severity (n, %) |
|-----------|-----------------------|------------------|----------------|
|           | 11.8±4.5              | 22 (52.4)        | 0 (No cough)  |
|           | 17.5±6.5              | 18 (42.9)        | 20 (47.6)     |
|           | 17.4±5.7              | 5 (11.9)         | 24 (57.1)     |
|           | 17.2±5.8              | 6 (14.3)         | 37 (88.1)     |
|           |                       |                  | 36 (85.7)     |
|           |                       |                  | 1 (Mild)      |
|           |                       |                  | 8 (19.0)      |
|           |                       |                  | 8 (19.0)      |
Table 2. Onset time, incidence and severity of cough in the four groups.

Onset time: from the end of fentanyl injection to the beginning of coughing.

\(^a P < 0.01, ^b P < 0.05\) compared to group 1, \(^c P < 0.05\) compared to group 2.

**Figure Legends**

Figure 1. Consolidated Standards of Reporting Trials (CONSORT) recommended description of patient recruitment

Figure 2. Effects of pretreatments on HR in the four groups.

HR: heart rate; bpm: beats/min.

T0: at the beginning of pretreatment; T1: 3 min after the beginning of pretreatment; T2: 6 min after the beginning of pretreatment; T3: 9 min after the beginning of pretreatment; T4: 12 min after the beginning of pretreatment.

\(^a P < 0.05, ^b P < 0.01\), compared to T0.

Figure 3. Effects of pretreatments on MAP in the four groups.
MAP: mean arterial pressure.

T0: at the beginning of pretreatment; T1: 3 min after the beginning of pretreatment; T2: 6 min after the beginning of pretreatment; T3: 9 min after the beginning of pretreatment; T4: 12 min after the beginning of pretreatment.

\* P < 0.05, compared to T0.

Methods

This prospective, randomized, double-blind, controlled clinical trial was approved by the Institutional Research Ethics Committee of the Affiliated Hospital of Yangzhou University, Yangzhou, China. All the participants provided written informed consent following principles of the Helsinki Declaration. Also, this study was registered in ClinicalTrials.gov (NCT03126422).

Participants

One hundred and eighty patients, ASA I or II, aged 18 - 65 years, BMI 18.5-30 kg/m², and scheduled for elective surgeries under general anesthesia between Oct 2017 and May 2018, were enrolled in the study. Exclusion criteria were patients with bradycardia (HR < 50 beats/min [14]), hypotension (blood pressure < 90/60 mmHg), impairment of liver or kidney, smoking, asthma, chronic cough, upper respiratory tract infection within the previous 2 weeks, or use of medications that could interfere with this study such as angiotensin-converting enzyme inhibitors, bronchodilators, or steroids.

Study protocol

This study was randomly assigned to four groups with 45 patients each depending on the 10-min pretreated dose of dexmedetomidine, using computer-generated random numbers: group 1 (0 mcg/kg), group 2 (0.3 mcg/kg), group 3 (0.6 mcg/kg) and group 4 (0.9 mcg/kg).

No premedication was used in all patients. Venous access was established on the wrist cephalic vein of the nondominant hand with a 20-G intravenous cannula after patients came into the pre-operation room and Ringers’ solution of 8 ml·kg⁻¹·h⁻¹ was transfused. The vertical distance from the drip bottle to the venous access was 80 centimeters in all the cases in this study. The IV cannula was connected to T-connectors for drugs infusion and injection in the operating theater. All patients were monitored with electrocardiogram, noninvasive blood pressure, and SpO₂ during the whole study.

Anesthesia induction was standardized and the procedure consisted of the following. Dexmedetomidine (200 mcg/2 ml; 181016BP, Hengrui Co., Jiangsu, China) was diluted with normal saline to a concentration of 4 mcg/ml. Patients were given dexmedetomidine by pumping at an intravenous dose of 0, 0.3, 0.6, and 0.9 mcg/kg over 10 mins in groups 1, 2, 3, and 4, respectively. In group 1, normal saline was used and the
infusion rate was set at 50 ml/h. All the pretreatments were prepared and implemented by an experienced anesthesiologist who was not involved in data collection. Also, all the priming drugs and the infusion pumps were covered with a piece of sheet. Oxygen supply through facemask was given to all the patients. Assisted ventilation was supplied if SpO₂ fell below 95% or decreased by 5% from initial value throughout the study. At 10 min after the beginning of pretreatment infusion, the pumping rate of dexmedetomidine was continued at 0.5 mcg·kg⁻¹·h⁻¹ in all the groups. Meanwhile, fentanyl (50 mcg/ml; 81D05031, Renfu Co., Hubei, China) 4 mcg/kg with the injection time of 5 s was given to all the patients. A stopwatch was used to control the time.

After fentanyl injection, the symptoms of irritating cough including the severity and onset time (the time from the end of fentanyl injection to the beginning of coughing) of cough were recorded for 1 min. Any occurrence of cough was identified as coughing. According to the number of coughs within 1 min after fentanyl injection[9], the severity of cough was classified to four grades: 0 (no cough), 1 (mild, 1-2 times), 2 (moderate, 3-5 times), and 3 (severe, > 5 times). The recording was done by an anesthesiologist who was unaware of the grouping criteria.

General anesthesia induction was continued following cough cessation or 1 min after fentanyl injection with midazolam 0.05 mg/kg, propofol 1.5-2.5 mg/kg and cisatracurium 0.2 mg/kg to facilitate endotracheal intubation or laryngeal mask insertion. Mechanical ventilation was controlled with tidal volume of 8 ml/kg, at a respiratory rate of 12 breaths/min. The beginning of pretreated-dexmedetomidine use was recorded at 0 min (T0). MAP, HR, and SpO₂ were recorded at T0, 3 min (T1), 6 min (T2), 9 min (T3) and 12 min (T4) after the beginning of pretreatment. Side effects of dexmedetomidine, such as bradycardia, hypertension, hypotension, and respiratory depression were recorded during the course. Ephedrine was used if MAP < 60 mmHg or the decrease of MAP > 30% of the basal data. Atropine was used if HR < 50 beats/min or the decrease of HR > 30% of the basal data. The relevant measures taken to deal with the side effects were also recorded. The above recordings were done by another anesthesiologist who was unaware of the grouping criteria.

**Sample size determination**

In our preliminary study, the incidence of FIC was 48%. A power analysis was performed using the incidence of FIC as the primary variable. We hypothesized that certain dose of 10-min dexmedetomidine priming infusion could reduce the incidence of FIC to 15%. To detect this difference with 90% power at a 5% significance level, 40 patients would be necessary in each group. Therefore, we recruited 45 patients for each group to allow missing data.

**Statistical analysis**

Statistical analysis was performed using Statistical Product for Social Sciences (SPSS) software 19.0 for windows. Data were expressed as mean ± SD, number, proportion, or percentage. Quantitative variables
were analyzed using one-way ANOVA with repeated measures between groups. One-way ANOVA and post Hoc Bonferroni multiple comparison test were used to compare differences of vital signs between groups after dexmedetomidine infusion and fentanyl injection. Ordinal data were compared with the Kruskal-Wallis test followed, when indicated, with Dunn’s multiple comparison tests. P value of < 0.05 was considered statistically significant.

Results

Study subjects

In total, 180 patients were surveyed for their eligibility. Of these patients, 5 did not meet the inclusion criteria, and 7 refused to participate. The remaining 168 patients were randomized into four groups (n = 42) and completed the study (Figure 1). There were no significant differences among the four groups with respect to demographic data including age, sex, BMI, and ASA physical status (P > 0.05) (Table 1).

Effects of pretreatments on incidence and severity of cough

There were 22 (52.4%), 18 (42.9%), 5 (11.9%), and 6 (14.3%) patients had coughs in groups 1, 2, 3, and 4, respectively. No significant differences between groups 1 and 2 and between groups 3 and 4 were found (P > 0.05). Compared to groups 1 and 2, the incidence of cough in groups 3 and 4 decreased significantly (P < 0.05). (Table 2)

The severity of cough in the four groups was shown in Table 2. There were no significant differences about it between groups 1 and 2 and between groups 3 and 4 (P > 0.05). The severity of cough decreased significantly in groups 3 and 4 compared to groups 1 and 2 (P < 0.05).

Effects of pretreatments on the onset time of cough

The onset time of cough was 11.8±4.5 s, 17.5±6.5 s, 17.4±5.7 s, and 17.2±5.8 s in groups 1, 2, 3, and 4, respectively (Table 2). Compared to group 1, the pretreatment of dexmedetomidine delayed FIC onset time significantly in groups 2, 3, and 4 (P < 0.05). However, there were no significant differences about it between groups 2, 3, and 4.

Safety

There were no significant differences in MAP and HR between groups 1, 2, and 3. Compared to T0, HR and MAP in groups 1, 2 and 3 were not significantly different at the other three time points (P > 0.05). In group 4, HR at T2 (P < 0.05), T3 (P < 0.05) and T4 (P < 0.01) decreased significantly compared to T0 (Figure 2); MAP at T4 decreased significantly compared to T0 (P < 0.01) (Figure 3). No serious adverse events occurred during the study. No bradycardia, hypertension, hypotension, or respiratory depression
occurred in groups 1, 2, and 3. While in group 4, one patient developed bradycardia and needed atropine treatment, and 1 patient had respiratory depression with SpO₂ < 95% and assisted ventilation was effective.

**Discussion**

The present study discovered that pretreatment with dexmedetomidine intravenous infusion of 0.6 mcg/kg bolus given over 10 mins reduced the severity of FIC effectively without adverse effects when fentanyl 4 mcg/kg was injected with the injection time of 5 s.

FIC deserves enough attention. Previous studies have shown that the incidence of FIC is about 35%-64% [1, 5, 15, 16]. These discrepancies may be due to differences in fentanyl injection dose, speeds, or routs. In this study, we used fentanyl 4 mcg/kg as the dose was usually adopted for general anesthesia induction in our daily work. We found that 52.4% patients had cough in the control group when fentanyl was injected through the wrist cephalic vein. A higher incidence of cough occurred in our control group than in some previous reports [4, 17], which was probably due to the rapid injection of fentanyl bolus (5 s of 4 mcg/kg) in our study. In clinical practice, fentanyl might be injected more slowly. Besides, there were more females in our study. Females are susceptible to FIC [18].

The mechanism of FIC has not been fully elucidated. However, a number of possible theories have been proposed: (1) The trigger stimulus and bronchial hyper-irritability theory might be a reason. Opioid receptors have been identified in the trachea, bronchi, and alveolar walls. The opioid receptors can be activated by fentanyl and airway smooth muscles can be triggered to constrict. Histamine and neuropeptides may be released by action on the prejunctional μ-opioid receptors after fentanyl injection. Irritating-cough then is produced [8, 19]; (2) A pulmonary chemoreflex is another likely mechanism, which is mediated by either irritant receptors or by vagal C-fiber receptors near pulmonary vessels [20]; (3) Muscle rigidity caused by fentanyl might induce sudden adduction of the vocal cords or supraglottic obstruction and cough might happen [20]; (4) The balance between sympathetic nerve and parasympathetic nerve may also have an effect on FIC [21]. The highly selective α₂-adrenergic agonist dexmedetomidine, with sedative and analgesic properties, is mostly used in clinical applications. Due to the central nervous system effect of fentanyl, we speculate that the suppression of FIC by preemptive infusion of dexmedetomidine might also be related to the fact that it could penetrate into blood brain barrier and suppress cough reflex by inhibiting the cough center directly due to its high lipid solubility [20].

Medications or mechanical measures have been used to relieve FIC [2, 21-23]. However, the effects varied from each other. In Liang H et al’s study, they found that intravenous dexmedetomidine (0.5 mcg/kg or 1 mcg/kg) immediately before fentanyl (4.0 mcg/kg) injection reduced the incidence of FIC [13]. The risk of bradycardia is significantly higher when the loading dose is greater than 0.7 mcg/kg [24]. It is practical to explore the applicability of different doses of dexmedetomidine and find out the optimal dose of pretreated-dexmedetomidine with effective suppression on FIC and without side effects. In clinical
practice, loading dose was often infused over 10 mins and a maintenance dose was then continued [25]. In the present study, dexmedetomidine was infused over 10 mins to achieve the steady plasma concentration.

In this study, we applied different doses of pretreated-dexmedetomidine intravenously to explore the optimal dose of dexmedetomidine in suppressing FIC. This study demonstrated that intravenous pretreatment of dexmedetomidine 0.6 mcg/kg bolus given over 10 mins could effectively decrease the incidence and severity of FIC. As was seen in group 4 in our study, compared to T0, MAP at T4 decreased significantly and HR at T2, T3, and T4 decreased significantly in group 4. This may be due to the exciting effects of α₂-adrenergic receptors of dexmedetomidine and the according decreased release of catecholamine. After pretreatment in group 4, HR decreased to below 50 beats/min in 1 patient and was treated with atropine effectively. SpO₂ was seen decreasing to below 95% in 1 case and increased to 100% after pressurized auxiliary ventilation during dexmedetomidine infusion also in group 4. The onset time of FIC in group 3 was about 17.4 sec later after fentanyl injection in this study. The peak plasma concentration of fentanyl in lung parenchyma could decrease over time because of its high lipid solubility and the absorption of other tissues. A low plasma concentration of fentanyl might not induce FIC. Prolonging the injection time of fentanyl over the time to reach the threshold of its plasma concentration could reduce the incidence and severity of FIC further.

There are still some limitations in this study. First, the judgment index of FIC incidence and degree is subjective, for no objective indicators have been found till now. Second, this study focused on clinical manifestation of the inhibitory effect of dexmedetomidine on FIC, while the specific physiological mechanism needs further study.

**Discussion**

The present study discovered that pretreatment with dexmedetomidine intravenous infusion of 0.6 mcg/kg bolus given over 10 mins reduced the severity of FIC effectively without adverse effects when fentanyl 4 mcg/kg was injected with the injection time of 5 s.

FIC deserves enough attention. Previous studies have shown that the incidence of FIC is about 35%-64% [1, 5, 15, 16]. These discrepancies may be due to differences in fentanyl injection dose, speeds, or routs. In this study, we used fentanyl 4 mcg/kg as the dose was usually adopted for general anesthesia induction in our daily work. We found that 52.4% patients had cough in the control group when fentanyl was injected through the wrist cephalic vein. A higher incidence of cough occurred in our control group than in some previous reports [4, 17], which was probably due to the rapid injection of fentanyl bolus (5 s of 4 mcg/kg) in our study. In clinical practice, fentanyl might be injected more slowly. Besides, there were more females in our study. Females are susceptible to FIC [18].

The mechanism of FIC has not been fully elucidated. However, a number of possible theories have been proposed: (1) The trigger stimulus and bronchial hyper-irritability theory might be a reason. Opioid
receptors have been identified in the trachea, bronchi, and alveolar walls. The opioid receptors can be activated by fentanyl and airway smooth muscles can be triggered to constrict. Histamine and neuropeptides may be released by action on the prejunctional μ-opioid receptors after fentanyl injection. Irritating-cough then is produced [8, 19]; (2) A pulmonary chemoreflex is another likely mechanism, which is mediated by either irritant receptors or by vagal C-fiber receptors near pulmonary vessels [20]; (3) Muscle rigidity caused by fentanyl might induce sudden adduction of the vocal cords or supraglottic obstruction and cough might happen [20]; (4) The balance between sympathetic nerve and parasympathetic nerve may also have an effect on FIC [21]. The highly selective α2-adrenergic agonist dexmedetomidine, with sedative and analgesic properties, is mostly used in clinical applications. Due to the central nervous system effect of fentanyl, we speculate that the suppression of FIC by preemptive infusion of dexmedetomidine might also be related to the fact that it could penetrate into blood brain barrier and suppress cough reflex by inhibiting the cough center directly due to its high lipid solubility [20].

Medications or mechanical measures have been used to relieve FIC [2, 21-23]. However, the effects varied from each other. In Liang H et al’s study, they found that intravenous dexmedetomidine (0.5 mcg/kg or 1 mcg/kg) immediately before fentanyl (4.0 mcg/kg) injection reduced the incidence of FIC [13]. The risk of bradycardia is significantly higher when the loading dose is greater than 0.7 mcg/kg [24]. It is practical to explore the applicability of different doses of dexmedetomidine and find out the optimal dose of pretreated-dexmedetomidine with effective suppression on FIC and without side effects. In clinical practice, loading dose was often infused over 10 mins and a maintenance dose was then continued [25]. In the present study, dexmedetomidine was infused over 10 mins to achieve the steady plasma concentration.

In this study, we applied different doses of pretreated-dexmedetomidine intravenously to explore the optimal dose of dexmedetomidine in suppressing FIC. This study demonstrated that intravenous pretreatment of dexmedetomidine 0.6 mcg/kg bolus given over 10 mins could effectively decrease the incidence and severity of FIC. As was seen in group 4 in our study, compared to T0, MAP at T4 decreased significantly and HR at T2, T3, and T4 decreased significantly in group 4. This may be due to the exciting effects of α2-adrenergic receptors of dexmedetomidine and the according decreased release of catecholamine. After pretreatment in group 4, HR decreased to below 50 beats/min in 1 patient and was treated with atropine effectively. SpO2 was seen decreasing to below 95% in 1 case and increased to 100% after pressurized auxiliary ventilation during dexmedetomidine infusion also in group 4. The onset time of FIC in group 3 was about 17.4 sec later after fentanyl injection in this study. The peak plasma concentration of fentanyl in lung parenchyma could decrease over time because of its high lipid solubility and the absorption of other tissues. A low plasma concentration of fentanyl might not induce FIC. Prolonging the injection time of fentanyl over the time to reach the threshold of its plasma concentration could reduce the incidence and severity of FIC further.

There are still some limitations in this study. First, the judgment index of FIC incidence and degree is subjective, for no objective indicators have been found till now. Second, this study focused on clinical manifestation of the inhibitory effect of dexmedetomidine on FIC, while the specific physiological mechanism needs further study.
Conclusions

In conclusion, the pretreated intravenous infusion of dexmedetomidine 0.6 mcg/kg bolus given over 10 mins before a 5-s injection of fentanyl 4 mcg/kg can suppress FIC effectively without side effects.

Abbreviations

FIC: Fentanyl-induced Cough; BMI: Body Mass Index; MAP: Mean Arterial Pressure; HR: Heart Rate; SpO₂: Pulse Oxygen Saturation.

Declarations

Ethics approval and consent to participate

This clinical trial was approved by the Institutional Research Ethics Committee of the Affiliated Hospital of Yangzhou University, Yangzhou, China. All the participants provided written informed consent following principles of the Helsinki Declaration.

Consent for publication

Not applicable.

Availability of data and material

The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

No funding was obtained for this study.

Authors' contributions

ZZ designed the study, drafted and wrote the manuscript. WZ, DSZ and SPT implemented the trial and contributed samples collection. YY and ZX prepared drugs. RRM and TQZ collected the data and did statistical analysis. TXB and JHS revised the manuscript critically. All authors gave intellectual input to the study and approved the final version of the manuscript.

Acknowledgements
The authors thank sincerely all the nursing staff in operating rooms for their efforts and performance and all the surgeon team for their cooperation during this study.

Statement

This study adheres to CONSORT guidelines.

References

1. Pandey CK, Raza M, Ranjan R, Singhal V, Kumar M, Lakra A, Navkar DV, Agarwal A, Singh RB, Singh U et al: Intravenous lidocaine 0.5 mg.kg-1 effectively suppresses fentanyl-induced cough. Can J Anaesth 2005, 52(2):172-175.

2. Tang Q, Qian Y, Zhang Q, Yang J, Wang Z: Effects of different priming doses of propofol on fentanyl-induced cough during anesthesia induction: a preliminary randomized controlled study. Ups J Med Sci 2010, 115(2):121-124.

3. Sedighinejad A, Naderi Nabi B, Haghighi M, Imantalab V, Hadadi S, Erfani Sayar R, Mirblook A: Propofol is Effective to Depress Fentanyl-Induced Cough during Induction of Anesthesia. Anesth Pain Med 2013, 2(4):170-173.

4. Pandey CK, Raza M, Ranjan R, Lakra A, Agarwal A, Singh U, Singh RB, Singh PK: Intravenous lidocaine suppresses fentanyl-induced coughing: a double-blind, prospective, randomized placebo-controlled study. Anesth Analg 2004, 99(6):1696-1698, table of contents.

5. Lin CS, Sun WZ, Chan WH, Lin CJ, Yeh HM, Mok MS: Intravenous lidocaine and ephedrine, but not propofol, suppress fentanyl-induced cough. Can J Anaesth 2004, 51(7):654-659.

6. Lim KJ, Lee SK, Lee HM, Park EY, Kim MH, Kim YS, Kang MH: Aspiration pneumonia caused by fentanyl-induced cough -a case report. Korean J Anesthesiol 2013, 65(3):251-253.

7. Ambesh SP, Singh N, Srivastava K: Fentanyl Induced Coughing Caused Life-threatening Airway Obstruction in a patient with arteriovenous malformation of tongue and hypopharynx. Internet Journal of Anesthesiology 2009.

8. Tweed WA, Dakin D: Explosive coughing after bolus fentanyl injection. Anesth Analg 2001, 92(6):1442-1443.

9. Yu H, Yang XY, Zhang X, Li Q, Zhu T, Wang Y, Liu B: The effect of dilution and prolonged injection time on fentanyl-induced coughing. Anaesthesia 2007, 62(9):919-922.

10. Horng HC, Wong CS, Hsiao KN, Huh BK, Kuo CP, Cherng CH, Wu CT: Pre-medication with intravenous clonidine suppresses fentanyl-induced cough. Acta Anaesthesiol Scand 2007, 51(7):862-865.
11. Li Y, Wang B, Zhang LL, He SF, Hu XW, Wong GT, Zhang Y: Dexmedetomidine Combined with General Anesthesia Provides Similar Intraoperative Stress Response Reduction When Compared with a Combined General and Epidural Anesthetic Technique. Anesth Analg 2016, 122(4):1202-1210.

12. Yu J, Lu Y, Dong C, Zhu H, Xu R: Premedication with intravenous dexmedetomidine-midazolam suppresses fentanyl-induced cough. Ir J Med Sci 2012, 181(4):517-520.

13. He L, Xu JM, Dai RP: Dexmedetomidine reduces the incidence of fentanyl-induced cough: a double-blind, randomized, and placebo-controlled study. Ups J Med Sci 2012, 117(1):18-21.

14. Kusumoto FM SM, Barrett C, Lee R, Edgerton JR, Marine JE, Ellenbogen KA, McLeod CJ, Gold MR, Oken KR, Goldschlager NF, Patton KK, Hamilton RM, Pellegrini CN, Joglar JA, Selzman KA, Kim RJ, Thompson A, Varosy PD: 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary. Heart Rhythm 2018.

15. Lui PW, Hsing CH, Chu YC: Terbutaline inhalation suppresses fentanyl-induced coughing. Can J Anaesth 1996, 43(12):1216-1219.

16. Bohrer H, Fleischer F, Werning P: Tussive effect of a fentanyl bolus administered through a central venous catheter. Anaesthesia 1990, 45(1):18-21.

17. Agarwal A, Gautam S, Nath SS, Gupta D, Singh U: Comparison of the incidence and severity of cough induced by sufentanil and fentanyl: a prospective, randomised, double-blind study. Anaesthesia 2007, 62(12):1230-1232.

18. Oshima T, Kasuya Y, Okumura Y, Murakami T, Dohi S: Identification of independent risk factors for fentanyl-induced cough. Can J Anaesth 2006, 53(8):753-758.

19. Agarwal A, Azim A, Ambesh S, Bose N, Dhiraj S, Sahu D, Singh U: Salbutamol, beclomethasone or sodium chromoglycate suppress coughing induced by iv fentanyl. Can J Anaesth 2003, 50(3):297-300.

20. Yeh CC, Wu CT, Huh BK, Lee MS, Lin SL, M JS, Wong CS: Premedication with intravenous low-dose ketamine suppresses fentanyl-induced cough. J Clin Anesth 2007, 19(1):53-56.

21. Ambesh SP, Singh N, Gupta D, Singh PK, Singh U: A huffing manoeuvre, immediately before induction of anaesthesia, prevents fentanyl-induced coughing: a prospective, randomized, and controlled study. Br J Anaesth 2010, 104(1):40-43.

22. Lin JA, Yeh CC, Lee MS, Wu CT, Lin SL, Wong CS: Prolonged injection time and light smoking decrease the incidence of fentanyl-induced cough. Anesth Analg 2005, 101(3):670-674, table of contents.

23. Hung KC: The possible mechanism of clonidine to suppress fentanyl-induced coughing. Acta Anaesthesiol Scand 2009, 53(9):1227-1228.
24. Tan JA, Ho KM: Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med 2010, 36(6):926-939.

25. Ko KH, Jun IJ, Lee S, Lim Y, Yoo B, Kim KM: Effective dose of dexmedetomidine to induce adequate sedation in elderly patients under spinal anesthesia. Korean J Anesthesiol 2015, 68(6):575-580.

**Tables**

Table 1. Demographic characteristics of patients in the four groups.

| Parameters         | Group 1          | Group 2          | Group 3          | Group 4          |
|--------------------|------------------|------------------|------------------|------------------|
| Age (years)        | 46.8±14.3        | 49.9±11.8        | 47.3±13.4        | 45.3±10.0        |
| Gender (males/females) | 19/23         | 20/22           | 18/24           | 21/21           |
| Weight (kg)        | 68.6±11.8        | 69.8±10.6        | 65.7±12.6        | 63.4±9.8         |
| BMI (kg/cm²)       | 24.5±2.8         | 25.1±3.2         | 24.2±3.6         | 23.0±2.3         |
| ASA (I/II)         | 24/18            | 26/16            | 26/16            | 25/17            |

Values are mean ± standard deviation.

Table 2. Onset time, incidence and severity of cough in the four groups.

| Cough               | Group 1          | Group 2          | Group 3ac         | Group 4ac         |
|---------------------|------------------|------------------|-------------------|-------------------|
| Onset time (s, ±s)  | 11.8±4.5         | 17.5±6.5b        | 17.4±5.7b         | 17.2±5.8b         |
| Incidence (n, %)    | 22 (52.4)        | 18 (42.9)        | 5 (11.9)          | 6 (14.3)          |
| Severity (n, %)     | 0 (No cough)     | 20 (47.6)        | 24 (57.1)         | 37 (88.1)         | 36 (85.7)         |
| (n, %)              | 1 (Mild)         | 8 (19.0)         | 8 (19.0)          | 3 (7.1)           | 5 (11.9)          |
|                     | 2 (Moderate)     | 8 (19.0)         | 6 (14.3)          | 1 (2.4)           | 1 (2.4)           |
|                     | 3 (Severe)       | 6 (14.3)         | 4 (9.5)           | 1 (2.4)           | 0 (0)             |

Onset time: from the end of fentanyl injection to the beginning of coughing.

a $P < 0.01$, b $P < 0.05$ compared to group 1, c $P < 0.05$ compared to group 2.

**Figures**
Figure 1

Consolidated Standards of Reporting Trials (CONSORT) recommended description of patient recruitment

![Consolidated Standards of Reporting Trials (CONSORT) recommended description of patient recruitment](image)

Figure 2

Effects of pretreatments on HR in the four groups. HR: heart rate; bpm: beats/min. T0: at the beginning of pretreatment; T1: 3 min after the beginning of pretreatment; T2: 6 min after the beginning of pretreatment; T3: 9 min after the beginning of pretreatment; T4: 12 min after the beginning of pretreatment. a P < 0.05, b P < 0.01, compared to T0.
Figure 3

Effects of pretreatments on MAP in the four groups. MAP: mean arterial pressure. T0: at the beginning of pretreatment; T1: 3 min after the beginning of pretreatment; T2: 6 min after the beginning of pretreatment; T3: 9 min after the beginning of pretreatment; T4: 12 min after the beginning of pretreatment. a P < 0.05, compared to T0.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- supplement1.doc
- supplement2.pdf